Sipai Health updated its prospectus and achieved revenue of 1.888 billion yuan in the first half of 2022

Songuo Finance has learned that Sipai Health Technology Co., Ltd. (hereinafter referred to as “Sipai Health”) will update the prospectus on October 27, 2022, and continue to promote the listing process of the main board of the Hong Kong Stock Exchange. Morgan Stanley and Haitong International are the joint sponsors. people.

At present, Sipai Health has three business lines: specialty drug pharmacy business, doctor research assistance and health insurance service. In the prospectus, Sipai Health stated that the net proceeds from the IPO will be mainly used for business expansion; technology research and development and upgrading of technology infrastructure.

It is reported that as of June 30, 2022, Supai Health operates 103 specialty drug pharmacies in all provincial-level administrative regions in mainland China except Tibet and Qinghai, which specialize in providing prescription drugs for cancer and other critical illnesses. According to CIC, the specialty drug pharmacy business of SuperHealth operates the largest private specialty drug pharmacy in terms of 2021 revenue.

As of June 30, 2022, Spiai Health’s test centers in 87 cities have served a total of 289 customers. It is worth mentioning that Sipai Health has achieved full coverage of 27 provincial oncology hospitals and five national cancer treatment centers.

As of June 30, 2022, SPI Health has completed 99 SMO projects and is in the process of 936 SMO projects, serving all the top ten listed pharmaceutical companies engaged in innovative drug research and development in China.

In addition, Sipai Health’s network of health service providers connects more than 1,200 tertiary hospitals, 55,000 doctors and 500 medical check-up institutions in more than 150 major cities in China. As of June 30, 2022, Supai Health served approximately 23.9 million individual members and 876 corporate customers.

Since its establishment, Sipai has completed a total of 8 rounds of financing. Investors include Tencent, F-Prime Capital, Eight Roads Capital, Times Capital, Ping An Ventures, IDG Capital, CLP CICC, Shengding Capital, Shuanghu Capital, Guangxi Yuan Capital, Wuyuan Capital, Zhongwei Capital, Taihe Capital, etc. have raised a total of US$574 million.